ImmuneRegen BioSciences, Inc. Confirms Homspera’s Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration

SCOTTSDALE, Ariz., July 29 /PRNewswire-FirstCall/ -- ImmuneRegen BioSciences(R), a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBS - News), reports preliminary evidence that its selective Neurokinin 1-receptor agonist Homspera® is both active on oral administration and provides therapeutic effects against the current pandemic H1N1 virus infection.